Market Cap 20.88M
Revenue (ttm) 1.23M
Net Income (ttm) -13.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,090.24%
Debt to Equity Ratio 0.00
Volume 413,800
Avg Vol 232,148
Day's Range N/A - N/A
Shares Out 1.65M
Stochastic %K 11%
Beta 2.14
Analysts Strong Sell
Price Target $29.80

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphom...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 9472 4101
Address:
Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, Australia
ocellated
ocellated Sep. 3 at 1:18 PM
$KZIA Why doesn't the company clarify how many patients are in the phase 1b tnbc trial and for how long each and what are all of the results? It is a very easy clarification. We know there are at least 6, but I have never seen where the company has said these are the only 6. It's hard to imagine the entities that received the offering did not perform due diligence on this.
0 · Reply
topstockalerts
topstockalerts Sep. 2 at 9:28 PM
$KZIA this looks like it wants higher honestly
1 · Reply
ocellated
ocellated Sep. 2 at 6:50 PM
$KZIA The intraday high for Aug 27 was $17.18, which would have made the market cap $196.36 million. The market cap after the upfront raise later that same day was $217.16 million, only $20.8 million additional market cap from that intraday high - today at $13.01/share, 139.065 million market cap. Net losses. What was the point of this dilution?
1 · Reply
StantheMan32
StantheMan32 Sep. 2 at 6:38 PM
$KZIA Potential signs of a bottoming process. Let's hope
0 · Reply
harambe_reborn
harambe_reborn Sep. 2 at 5:04 PM
$KZIA sexy candle on the daily $12 bottom sounds good to me
0 · Reply
10baggerPete
10baggerPete Sep. 2 at 3:00 PM
$KZIA fascinating stuff. Long térm the data will determine the price. Short term, only God knows what shenanigans will hit the tape. Next short report will be interesting.
0 · Reply
PT3
PT3 Sep. 2 at 6:43 AM
$KZIA this chart matters much more going forward and many of us know the history that goes with that trajectory from your chart and I didn’t buy at once but absolutely did over time. Over next year to 2 you will see both charts provide an upward trajectory.
0 · Reply
Florestan
Florestan Sep. 2 at 6:07 AM
$KZIA I ask that the people investing in a company with this chart have some humility, especially when tagging other larger companies/boards.
1 · Reply
PT3
PT3 Sep. 2 at 5:47 AM
$KZIA this a very impressive indeed…
2 · Reply
PT3
PT3 Sep. 2 at 5:37 AM
$KZIA I agree it is annoying, but perhaps they have calculated what was necessary to get a multi-billion dollar offer from suitors. Maybe 1 billion soon or multi-billion closer to milestones. They are on a trajectory towards the $40 billion pathway over 3 to 5 years, but not overnight. The extra $80,000,000 will mean nothing whenever an offer is made, but in reality, it solidifies the confidence in Kazia’s assets and program. I believe that it may be annoying, but what is required for a bigger offer now or a much larger offer in 1 year or less. Maybe 4 multiples now on low side, which I doubt they would even consider, to maybe 10 or more in less than a year as suitors will certainly start lining up and know the value will only go up as more time passes…
1 · Reply
Latest News on KZIA
Kazia Therapeutics announces offering of ADS, warrants

2026-08-27T20:16:07.000Z - 7 days ago

Kazia Therapeutics announces offering of ADS, warrants


Kazia Therapeutics Limited Announces Proposed Public Offering

Aug 27, 2026, 4:09 PM EDT - 7 days ago

Kazia Therapeutics Limited Announces Proposed Public Offering


Kazia Therapeutics initiated with a Buy at Canaccord

2026-08-17T08:30:55.000Z - 17 days ago

Kazia Therapeutics initiated with a Buy at Canaccord


Kazia Therapeutics initiated with a Buy at BTIG

2026-07-01T10:41:06.000Z - 2 months ago

Kazia Therapeutics initiated with a Buy at BTIG


Kazia Therapeutics initiated with a Buy at Lake Street

2026-06-11T11:46:17.000Z - 2 months ago

Kazia Therapeutics initiated with a Buy at Lake Street


Kazia Therapeutics appoints James Levine as CFO

2026-06-02T12:29:05.000Z - 3 months ago

Kazia Therapeutics appoints James Levine as CFO


Kazia Therapeutics initiated with a Buy at Laidlaw

2026-04-15T09:06:21.000Z - 4 months ago

Kazia Therapeutics initiated with a Buy at Laidlaw


Kazia Therapeutics trading resumes

2026-01-02T21:00:10.000Z - 8 months ago

Kazia Therapeutics trading resumes


Kazia Therapeutics trading halted, volatility trading pause

2026-01-02T20:50:08.000Z - 8 months ago

Kazia Therapeutics trading halted, volatility trading pause


Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Dec 22, 2025, 8:00 AM EST - 8 months ago

Kazia Therapeutics Regains Full Nasdaq Listing Compliance


KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Sep 12, 2024, 7:30 AM EDT - 1 year ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER


Kazia announces presentation of new data at AACR Annual Meeting

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Kazia announces presentation of new data at AACR Annual Meeting


KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Jan 18, 2024, 7:30 AM EST - 2 years ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS


ocellated
ocellated Sep. 3 at 1:18 PM
$KZIA Why doesn't the company clarify how many patients are in the phase 1b tnbc trial and for how long each and what are all of the results? It is a very easy clarification. We know there are at least 6, but I have never seen where the company has said these are the only 6. It's hard to imagine the entities that received the offering did not perform due diligence on this.
0 · Reply
topstockalerts
topstockalerts Sep. 2 at 9:28 PM
$KZIA this looks like it wants higher honestly
1 · Reply
ocellated
ocellated Sep. 2 at 6:50 PM
$KZIA The intraday high for Aug 27 was $17.18, which would have made the market cap $196.36 million. The market cap after the upfront raise later that same day was $217.16 million, only $20.8 million additional market cap from that intraday high - today at $13.01/share, 139.065 million market cap. Net losses. What was the point of this dilution?
1 · Reply
StantheMan32
StantheMan32 Sep. 2 at 6:38 PM
$KZIA Potential signs of a bottoming process. Let's hope
0 · Reply
harambe_reborn
harambe_reborn Sep. 2 at 5:04 PM
$KZIA sexy candle on the daily $12 bottom sounds good to me
0 · Reply
10baggerPete
10baggerPete Sep. 2 at 3:00 PM
$KZIA fascinating stuff. Long térm the data will determine the price. Short term, only God knows what shenanigans will hit the tape. Next short report will be interesting.
0 · Reply
PT3
PT3 Sep. 2 at 6:43 AM
$KZIA this chart matters much more going forward and many of us know the history that goes with that trajectory from your chart and I didn’t buy at once but absolutely did over time. Over next year to 2 you will see both charts provide an upward trajectory.
0 · Reply
Florestan
Florestan Sep. 2 at 6:07 AM
$KZIA I ask that the people investing in a company with this chart have some humility, especially when tagging other larger companies/boards.
1 · Reply
PT3
PT3 Sep. 2 at 5:47 AM
$KZIA this a very impressive indeed…
2 · Reply
PT3
PT3 Sep. 2 at 5:37 AM
$KZIA I agree it is annoying, but perhaps they have calculated what was necessary to get a multi-billion dollar offer from suitors. Maybe 1 billion soon or multi-billion closer to milestones. They are on a trajectory towards the $40 billion pathway over 3 to 5 years, but not overnight. The extra $80,000,000 will mean nothing whenever an offer is made, but in reality, it solidifies the confidence in Kazia’s assets and program. I believe that it may be annoying, but what is required for a bigger offer now or a much larger offer in 1 year or less. Maybe 4 multiples now on low side, which I doubt they would even consider, to maybe 10 or more in less than a year as suitors will certainly start lining up and know the value will only go up as more time passes…
1 · Reply
LabMan
LabMan Sep. 2 at 3:40 AM
$KZIA Stan making sense. We have confirmation hedge funds - vultures, mostly took part in the raise. They are not interested in the drug or the company. So consequently, a big scramble to exit the position taken up a few days earlier & rely on the warrents locked in. They don't have to convert the warrents, all price dependant at the time. Can't lose seemingly, except longer term shareholders in the company are extremely disappointed, at again the competence level shown by the company.... All we have seen is selling. No need for the raise, at this time. The 6 out 6 patients news could have seen the SP over $30 today - but oh no, they butcher it again for nobody to gain. Raise could have been undertaken a week after TNBC results next year @ probably closer to $40 (or a not unreasonable float size of $400M or SP $38
0 · Reply
PT3
PT3 Sep. 1 at 10:54 PM
$KZIA I would keep in mind that the milestone linked are not exercised. If some major Big Pharma doesn’t buy Kazia out at 5-10 billion they have a plan to continue without them and with what appears the best in class Pi3k inhibitor THAT crosses the BBB and is taken orally :-) Buy, hold and win!!!
0 · Reply
ocellated
ocellated Sep. 1 at 10:45 PM
$KZIA So no updates? Just final readout in 2nd half 2027.
0 · Reply
Rinnekin
Rinnekin Sep. 1 at 10:20 PM
$KZIA A picture says more than many PRs … Putting the latest news together, bull case:
2 · Reply
ocellated
ocellated Sep. 1 at 10:08 PM
$KZIA Again the internet A I states that the exact number of patients in the tnbc trial has not been disclosed by the company. I’m thinking all of the institutional investors who are set to pay 120 million dollars for the new issues did that due diligence? Selective disclosure is not allowed. How many patients are in the phase 1b tnbc trial? For how long each? And what are the results? Any other pertinent info we are entitled to know?
1 · Reply
StantheMan32
StantheMan32 Sep. 1 at 8:48 PM
$KZIA had graduated from the sewer with a clean cap structure. Now they fu#ked it back up with 200% warrant overhang. Did they get poor advice? New CFO Levine asleep at the wheel. Credibility counts. They look like dopes. Short term pain was avoidable. Stock could have run for an ATM tap in the mid 20's. Then a straight common deal.
0 · Reply
reality90210
reality90210 Sep. 1 at 6:47 PM
$KZIA ok i have a question for those that listened to the call. Did anyone ask him how project frontrunner is doing? What happened to the fda type c meeting?
0 · Reply
futureexmillionare
futureexmillionare Sep. 1 at 5:03 PM
$KZIA next PR should be minutes from FDA meeting and this blast to $30-$40
1 · Reply
HappyStockholder
HappyStockholder Sep. 1 at 4:56 PM
$KZIA Be wary of those who compare KZIA to CELC. They are scammers and shills. If they truly had faith in KZIA they would tout it for its unique value, not draw baseless comparisons. Please…..allow KZIA to stand on its own two legs, if you truly believe in it.
0 · Reply
agamemnus
agamemnus Sep. 1 at 3:23 PM
$KZIA I guess the main problem is this is tied to semis.
0 · Reply
PT3
PT3 Sep. 1 at 3:22 PM
$KZIA expecting potentially more of this nonsense manipulation and accumulation for a bit, before it double or triples… 🥱
1 · Reply
StantheMan32
StantheMan32 Sep. 1 at 2:42 PM
$KZIA Also in from Twitter feed: Canaccord note out with positive comments. Re-iterates $29 target
0 · Reply